The sustained-release formulation of propafenone is significantly superior to placebo in preventing symptoms of paroxysmal atrial fibrillation, European researchers report in the December 15th issue of the American Journal of Cardiology.
Dr. Gregory Y. H. Lip of City Hospital, Birmingham, UK, and colleagues note that the extended-release version of the agent has been developed in minimize plasma concentration fluctuations and thereby improve compliance, efficacy and safety.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!